Form 8-K - Current report:
SEC Accession No. 0001193125-19-321791
Filing Date
2019-12-23
Accepted
2019-12-23 08:03:13
Documents
12
Period of Report
2019-12-17
Items
Item 1.01: Entry into a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 8-K d803912d8k.htm   iXBRL 8-K 25684
  Complete submission text file 0001193125-19-321791.txt   144750

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA sgmo-20191217.xsd EX-101.SCH 3068
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE sgmo-20191217_lab.xml EX-101.LAB 17375
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE sgmo-20191217_pre.xml EX-101.PRE 10952
8 EXTRACTED XBRL INSTANCE DOCUMENT d803912d8k_htm.xml XML 3280
Mailing Address 501 CANAL BLVD POINT RICHMOND TECH CNTR. RICHMOND CA 94804
Business Address 501 CANAL BLVD POINT RICHMOND TECH CNTR. RICHMOND CA 94804 5109706000
SANGAMO THERAPEUTICS, INC (Filer) CIK: 0001001233 (see all company filings)

EIN.: 680359556 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-30171 | Film No.: 191303458
SIC: 2836 Biological Products, (No Diagnostic Substances)